|
市場調查報告書
生物科技中技術轉移的機會構築 : 贊助商與開發業者的成功戰略
Building Biotech Technology Transfer Opportunities: Sponsor and developer strategies for success
|
生物科技中技術轉移的機會構築 : 贊助商與開發業者的成功戰略 是由出版商Business Insights在2010年02月所出版的。
這份英文市場調查報告書包含137 pages 價格從美金3835起跳。
研究開發費的高漲與暢銷藥品的專利失效而使製藥公司承受種種的壓力。為了維持競争力而進行技術轉移以期能建立更廣泛的關係，卻多以失敗告終。
本報告書為生物科技技術轉移之概要統整，各廠的案例分享中共通的陷阱以及最佳方案的驗證，概述如下。
總綱
第1章 生物科技中的技術轉移概要
- 大綱
- 生物科技業界現狀
- 藥劑開發的課題
- 生物科技的技術轉移關係種類
- 近年交易量
- 關係動向
- 結論
第2章 為何生物科技的技術轉移會失敗
第3章 使生物科技的技術轉移能成功所應有的戰略
第4章 將來的生物科技技術轉移契約
- 大綱
- 導論
- 將來的藥劑開發
- 生物科技：2010∼2015年
- 生物科技技術轉移動向：2010∼2015年
- 結論
目錄
圖表
Abstract
Drug developers have long been under pressure to introduce new products in an
environment of escalating R&D costs, blockbuster patent expiration and
resulting generic competition. Current weak economic conditions have
exacerbated these challenges with sweeping R&D staff and budget reductions. In
order to remain competitive, drug makers must now do more with less.
Technology transfer, particularly of new biotechnologies that offer novel
means to address unmet medical needs, offer a way to cost effectively address
these challenges. They also provide technology developers with a mechanism to
monetize their inventions. However, while some drug makers and technology
developers have optimized their biotech tech transfer methodologies and have
developed sophisticated processes to select, monitor and manage a wide range
of relationships, many other biotech tech transfer projects fail. A large
proportion of these failures could be averted as many of the most common
reasons for failure are preventable problems relating to due diligence
failures, shortcomings in deal structure, management changes, cultural
challenges, and inappropriate project organization and expectations. This
report provides details on how to avoid these common pitfalls with case
studies that illustrate best practices.
Table of Contents
Executive Summary
- Overview of biotech tech transfer
- Why biotech tech transfer deals fail
- Strategies to ensure successful biotech tech transfer deals
- The future of biotech tech transfer deals
Chapter 1 Overview of biotech tech transfer
- Summary
- The biotechnology industry today
- Biotechnology technologies and techniques
- Proliferation of investigational products
- Funding issues
- Need to partner to advance product development
- The emergence of biotechnology brokers
- Drug development challenges
- More complicated disease targets
- Escalating costs
- Increased regulatory scrutiny
- Diminished in-house R&D resources
- Types of biotech tech transfer relationships
- Academic R&D infusions
- Biotech biotech deals
- Pharma biotech alliances
- Licensing
- R&D collaborations
- Sales, distribution and co-marketing agreements
- Joint ventures
- Acquisitions
- Volume of recent deals
- Relationship trends
- Volume and value
- Ownership
- Conclusion
Chapter 2 Why biotech tech transfer deals fail
- Summary
- High failure rates
- Symptoms of deal failure
- Factors that do not affect deal failure
- Implications of deal failure
- Impact on technology developers
- Impact on technology sponsors
- Lost value of failed deals
- Main causes of biotech tech transfer failure
- Due diligence failures
- Technology performance
- Patent issues
- Developer organization strength
- Deal structure
- Management changes
- Cultural differences
- Project organization and expectations
- Other preventable problems
- Technology failure
- Conclusion
Chapter 3 Strategies to ensure successful biotech tech transfer deals
- Summary
- Measures of success
- Success for the technology developer
- Success for the technology sponsor
- Key biotech tech transfer strategies
- Strategies for both technology developers and sponsors
- Meeting technology challenges
- Strategies for technology developers
- Optimizing resources
- Thinking like a customer
- Working with professional tech transfer organizations
- Prolific publishing
- Strategies for technology sponsors
- Thorough technology identification and due diligence
- Structuring innovative deal terms
- Addressing compensation issues
- Fostering an entrepreneurial developer environment
- Ensuring effective alliance management
- Navigating cultural chasms
- Addressing international intellectual property challenges
- Conclusion
Chapter 4 The future of biotech tech transfer deals
- Summary
- Introduction
- The future of drug development
- Impact of the economy
- US healthcare reform
- Biosimilars
- Biotechnology in 2010 - 2015
- Where biotech fits into Big Pharma
- Dedicated biotechnology companies
- Biotech tech transfer deal trends 2010 - 2015
- Volume and value
- Ownership
- Intellectual property issues
- Success rates
- Conclusion
Index
List of Figures
- Figure 1.1: Frequency of biotech tech transfer deals by type of institution
- Figure 1.2: Number and volume of biopartnering deals, 1997 - 2009
- Figure 1.3: Acquisitions as a proportion of biotech tech transfer deals,
- Figure 2.4: Characteristics of biotech tech transfer failure causes
- Figure 2.5: Relative importance to sponsor of technology developer
- Figure 3.6: Strategies to optimize biotech tech transfer opportunities
- Figure 4.7: Biopharmaceutical vs. other pharmaceutical sales, 2009 - 2015
- Figure 4.8: Impact of industry and economic trends on conventional and
biotech drug developers, 2009 - 2015
- Figure 4.9: Relative importance of biotechnology for leading
pharmaceutical companies, 2009 2015
- Figure 4.10: Number and average size of global biotech companies, 2009 -
2015
- Figure 4.11: Number and volume of biopartnering deals, 2009 - 2015
List of Tables
- Table 1.1: Definition of biotechnology techniques
- Table 1.2: Biotech tech transfer deals, 2009
- Table 1.3: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.4: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.5: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.6: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.7: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.8: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.9: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.10: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.11: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.12: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.13: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.14: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.15: Biotech tech transfer deals, 2009 (Contd.)
- Table 1.16: Biotech tech transfer deals, 2009 (Contd.)
- Table 3.17: Technology transfer areas of interest for Merck & Co., 2010
- Table 3.18: Technology transfer areas of interest for Merck & Co., 2010
(Contd.)
- Table 3.19: Novartis private equity fund holdings, 2010
- Table 3.20: Novartis private equity fund holdings, 2010 (Contd.)
- Table 3.21: Novartis private equity fund holdings, 2010 (Contd.)
- Table 3.22: Novartis private equity fund holdings, 2010 (Contd.)
- Table 4.23: Millions of older and overweight persons in the US and EU,
2009 - 2015
- Table 4.24: Biosimilars approved in the US and EU, 2010
|
